Lundbeck files application for approval of Cipralex for the treatment of GAD  

2004.12.21
Lundbeck has filed an application with the health authorities in Sweden to gain EU approval of its antidepressant Cipralex for the treatment of generalised anxiety disorder (GAD)

Lundbeck has filed an application with the health authorities in Sweden to gain EU approval of its antidepressant Cipralex [escitalopram oxalate, called Lexapro in US - Ed] for the treatment of generalised anxiety disorder (GAD). According to Lundbeck, clinical studies have shown that Cipralex has effect on both depression and anxiety. Anders Gersel Pedersen, director of Lundbeck's drug development, says this is an advantage since patients often suffer from both disorders.

 

GAD is a relatively common anxiety problem affecting about 8% of the worldwide population at some point in their lives, and nearly 20 million people were estimated to be suffering from GAD in the western world in 2002.

 

Lundbeck is headquartered in Copenhagen and employs approx. 5,000 people. The pharmaceutical company is engaged in R&D, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2003, the company generated revenues of DKK 9.9 bn (USD 1.8 bn).

 

Link > Lundbeck 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×